- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04378439
Appalachisk partnerskap for å redusere forskjeller (mål 2)
Utnytte kraften til kolleganavigasjon og mHealth for å redusere helseforskjeller i Appalachia
By combining two strategies (i.e., peer navigation and mHealth) into a complete, culturally compatible, bilingual intervention to increase the use of needed HIV, STI, and HCV prevention and care services among racially/ethnically diverse GBMSM and transgender women in rural Appalachia.
Study Investigators anticipate that participants in the intervention group, relative to counterparts in the delayed-intervention group, will demonstrate increased HIV, STI, and HCV testing.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This CBPR study will advance prevention science and practice through testing an innovative intervention to promote and support the use of needed HIV, STI, and HCV prevention and care services among GBMSM and transgender women; and developing priorities and recommendations to improve their health that will be disseminated to inform public health practice, research, and policy. By integrating peer navigation and mHealth strategies, the proposed study provides a unique opportunity to improve health among vulnerable, hidden, and neglected populations living in rural Appalachia. Findings from this research may inform strategies and approaches to address other health disparities in other rural populations.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
North Carolina
-
Winston-Salem, North Carolina, Forente stater, 27157
- Wake Forest University Health Sciences
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- reside in one of the rural Appalachian catchment counties
- be ≥18 years of age
- report being assigned male sex at birth and having had sex with at least 1 man in past 12 months
- provide informed consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: intervention group
7 community health leaders; 56 social network members |
First, as health advisors, community health leaders will raise awareness of HIV, STIs, and HCV and local prevention and care services and help social network members access services. Thus, the community health leader will describe to the process for HCV testing, and how providers are required to maintain confidentiality. As opinion leaders, community health leaders will reframe health-compromising and bolster health-promoting norms and expectations about testing and use of other prevention and care services. Each community health leader will also conduct formal in-person group activities with their social network members. Our partnership decided that each community health leader will also hold at least 4 formal group sessions during the 12 months of intervention In addition to in-person individual and group activities, community health leaders will use mHealth platforms preferred by each social network member (i.e., Facebook , Instagram, testing, and/or GPS-based mobile apps) to communicate with them during the intervention. They will use social media to plan activities and to support use of needed prevention and care services. For example, when planning a group activity (described above), the community health leader will use social media to remind social network members about the activity and help them problem solve barriers to attending. A community health leader and social network member may also communicate "in-real-time" via social media about the process of participating in a syringe services program or accessing PrEP. |
|
Aktiv komparator: delayed-intervention
7 community health leaders; 56 social network members |
First, as health advisors, community health leaders will raise awareness of HIV, STIs, and HCV and local prevention and care services and help social network members access services. Thus, the community health leader will describe to the process for HCV testing, and how providers are required to maintain confidentiality. As opinion leaders, community health leaders will reframe health-compromising and bolster health-promoting norms and expectations about testing and use of other prevention and care services. Each community health leader will also conduct formal in-person group activities with their social network members. Our partnership decided that each community health leader will also hold at least 4 formal group sessions during the 12 months of intervention In addition to in-person individual and group activities, community health leaders will use mHealth platforms preferred by each social network member (i.e., Facebook , Instagram, testing, and/or GPS-based mobile apps) to communicate with them during the intervention. They will use social media to plan activities and to support use of needed prevention and care services. For example, when planning a group activity (described above), the community health leader will use social media to remind social network members about the activity and help them problem solve barriers to attending. A community health leader and social network member may also communicate "in-real-time" via social media about the process of participating in a syringe services program or accessing PrEP. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antall deltakere som har testet humant immunsviktvirus (HIV).
Tidsramme: grunnlinje
|
grunnlinje
|
|
Antall deltakere som har testet seksuelt overførbar infeksjon (STI).
Tidsramme: grunnlinje
|
grunnlinje
|
|
Antall deltakere som har testet hepatitt C-virus (HCV).
Tidsramme: grunnlinje
|
grunnlinje
|
|
Antall deltakere som har HIV-testing
Tidsramme: umiddelbart etter intervensjon (12 måneder etter baseline)
|
umiddelbart etter intervensjon (12 måneder etter baseline)
|
|
Antall deltakere som har STI-testing
Tidsramme: umiddelbart etter intervensjon (12 måneder etter baseline)
|
umiddelbart etter intervensjon (12 måneder etter baseline)
|
|
Antall deltakere som har HCV-testing
Tidsramme: umiddelbart etter intervensjon (12 måneder etter baseline)
|
umiddelbart etter intervensjon (12 måneder etter baseline)
|
|
Antall deltakere som har HIV-testing
Tidsramme: 12 måneders oppfølging (24 måneder etter baseline)
|
12 måneders oppfølging (24 måneder etter baseline)
|
|
Antall deltakere som har STI-testing
Tidsramme: 12 måneders oppfølging (24 måneder etter baseline)
|
12 måneders oppfølging (24 måneder etter baseline)
|
|
Antall deltakere som har HCV-testing
Tidsramme: 12 måneders oppfølging (24 måneder etter baseline)
|
12 måneders oppfølging (24 måneder etter baseline)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Antall deltakere som bruker forebygging - Pre-eksponeringsprofylakse (PrEP)
Tidsramme: baseline, umiddelbar post-intervensjon (12 måneder etter baseline), og 12-måneders oppfølging (24 måneder post-baseline).
|
baseline, umiddelbar post-intervensjon (12 måneder etter baseline), og 12-måneders oppfølging (24 måneder post-baseline).
|
|
|
Antall deltakere som bruker forebygging - sprøytetjenester
Tidsramme: baseline, umiddelbar post-intervensjon (12 måneder etter baseline), og 12-måneders oppfølging (24 måneder post-baseline).
|
baseline, umiddelbar post-intervensjon (12 måneder etter baseline), og 12-måneders oppfølging (24 måneder post-baseline).
|
|
|
Number of participants who use HIV care services
Tidsramme: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).
|
Measured through self-report and medical chart abstraction |
baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).
|
|
Number of participants who use STI treatment services
Tidsramme: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).
|
Measured through self-report and medical chart abstraction |
baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).
|
|
Number of participants who use HCV treatment services
Tidsramme: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).
|
Measured through self-report and medical chart abstraction |
baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).
|
|
Number of participants who use gender-affirming care services
Tidsramme: baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).
|
Measured through self-report and medical chart abstraction |
baseline, immediate post-intervention (12 months post-baseline), and 12-month follow-up (24 months post-baseline).
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Scott D. Rhodes, Ph.D, MPH, Wake Forest University Health Sciences
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Blodbårne infeksjoner
- Urogenitale sykdommer
- Kjønnssykdommer
- Patologiske prosesser
- Sykdomsattributter
- Sykdommer i immunsystemet
- Infeksjoner
- RNA-virusinfeksjoner
- Virussykdommer
- Smittsomme sykdommer
- Seksuelt overførbare sykdommer, virale
- Lentivirus infeksjoner
- Retroviridae-infeksjoner
- Immunologiske mangelsyndromer
- Langsomme virussykdommer
- HIV-infeksjoner
- Patologiske tilstander, tegn og symptomer
- Ervervet immunsviktsyndrom
- Seksuelt overførbare sykdommer
- Health Services Administration
- Levering av helsehjelp
- Pasientbehandling
- Telemedisin
Andre studie-ID-numre
- IRB00065116
- R01NR019512 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .